Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation

References

• World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021. [cited 5 June 2022]. https://www.who.int/publications/i/item/9789240027077
   Google Scholar
• Ly KN, Xing J, Monina Klevens R, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–278.
   PubMed Web of Science ®Google Scholar
• Wilby KJ, Partovi N, Ford JAE, et al. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012;26(4):205–210.
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Sagnelli C, et al. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9(4):e94542.
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132–142.
   PubMed Web of Science ®Google Scholar
• Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int. 2012;32:32–38.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55(5):1620–1628.
   PubMed Web of Science ®Google Scholar
• González-Grande R, Jiménez-Pérez M, Arjona CG, et al. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421–1432.
   PubMed Web of Science ®Google Scholar
• Sovaldi® (Sofosbuvir) tablets, for oral use. Full prescribing information n.d.
   Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014;23(4):561–571.
   PubMed Web of Science ®Google Scholar
• Smith MA, Regal RE, Mohammad RA. Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016;50(1):39–46.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences I. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use. US Prescr Inf. Foster City, CA: Gilead Sciences; October 2014. p. 32.
   Google Scholar
• Raedler LA. Viekira pak (Ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): all-oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Heal Drug Benefits. 2015;8:142–147.
   PubMedGoogle Scholar
• El Kassas M, Elbaz T, El Latif Y A, et al. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016;9(11):1413–1421.
   PubMed Web of Science ®Google Scholar
• Keating GM. Elbasvir/Grazoprevir: first global approval. Drugs. 2016;76(5):617–624.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Glecaprevir/Pibrentasvir: first global approval. Drugs. 2017;77(16):1797–1804.
   PubMed Web of Science ®Google Scholar
• Voaklander R, Jacobson IM. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017;11(9):789–795.
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.
   PubMed Web of Science ®Google Scholar
• Lemm JA, O’Boyle D, Liu M, et al. Identification of Hepatitis C Virus NS5A Inhibitors. J Virol. 2010;84(1):482–491.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015; 75(5):515–524. doi:10.1007/s40265-015-0362-5.
   PubMed Web of Science ®Google Scholar
• Suzuki F, Hatanaka N, Bando E, et al. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan. Hepatol Int. 2018;12(3):244–253.
   PubMed Web of Science ®Google Scholar
• Oh JY, Kim BS, Lee CH, et al. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med. 2019;34(4):794–801.
   PubMed Web of Science ®Google Scholar
• Gandhi Y, Eley T, Fura A, et al. Daclatasvir: a review of preclinical and clinical pharmacokinetics. Clin Pharmacokinet. 2018;57(8):911–928.
   PubMed Web of Science ®Google Scholar
• Takaguchi K, Toyoda H, Tsutsui A, et al. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2019;54(8):15–23.
   Web of Science ®Google Scholar
• Keating GM. Daclatasvir: a review in chronic hepatitis C. Drugs. 2016;76(14):1381–1391.
   PubMed Web of Science ®Google Scholar
• Fridell RA, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85(14):7312–7320.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol. 2020;73:1170–1218.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American association for the study of liver diseases–infectious diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018. [cited 20 June 2022]. https://www.who.int/publications/i/item/9789241550345
   Google Scholar
• Ridruejo E, Cheinquer H, Marciano S, et al. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. J Viral Hepat. 2019;26(10):1200–1209.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Morio K, Imamura M, Kawakami Y, et al. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. J Gastroenterol Hepatol. 2017;32(3):645–650.
   PubMed Web of Science ®Google Scholar
• Belperio PS, Shahoumian TA, Loomis TP, et al., Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70(1):15–23.
   PubMed Web of Science ®Google Scholar
• Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016;36(7):971–976.
   PubMed Web of Science ®Google Scholar
• Lacombe K, Fontaine H, Dhiver C, et al. Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access cohort. J Acquir Immune Defic Syndr. 2017;75(1):97–107.
   PubMed Web of Science ®Google Scholar
• Suda G, Furusyo N, Toyoda H, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018;53(1):119–128.
   PubMed Web of Science ®Google Scholar
• V KK, Gordon SC, Reddy KR, et al. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. Hepatology. 2015;61(4):1127–1135.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Li J, Zhang Y, et al. Real-world effectiveness of direct-acting antiviral regimens against hepatitis C virus (HCV) genotype 3 infection: a systematic review and meta-analysis. Ann Hepatol. 2021;23:100268.
   PubMed Web of Science ®Google Scholar
• Sarwar S, Tarique S, Aleem A, et al. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol. 2019;31(8):1035–1039.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354–369.
   PubMed Web of Science ®Google Scholar
• Butt Z, Shah SMA. Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic hepatitis c genotype 3a in Pakistani population-a real world experience. Pak J Med Sci. 2019;35:409–413.
   PubMed Web of Science ®Google Scholar
• Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421–431.
   PubMed Web of Science ®Google Scholar
• Nagaty A, Helmy SHA, Abd El-Wahab EW. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans R Soc Trop Med Hyg. 2020;114(3):200–212.
   PubMed Web of Science ®Google Scholar
• Zhang M, O’Keefe D, Iwamoto M, et al. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. J Viral Hepat. 2020;27(9):886–895.
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60(3):490–499.
   PubMed Web of Science ®Google Scholar
• Kao JH, Lee YJ, Heo J, et al. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36(10):1433–1441.
   PubMed Web of Science ®Google Scholar
• Kwo P, Fried MW, Reddy KR, et al. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun. 2018;2(4):354–363.
   PubMed Web of Science ®Google Scholar
• Schmelzer J, Dugan E, Blach S, et al., Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5(4):374–392.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Updated recommendations on treatment of adolescents and children with chronic HCV infection. 2022. [cited 20 October 2022]. https://www.who.int/publications/i/item/9789240052710
   Google Scholar
• Boyer S, Baudoin M, Nishimwe ML, et al., Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. BMC Health Serv Res. 2022;22(1):1–15.
   PubMed Web of Science ®Google Scholar
• van de Ven N, Fortunak J, Simmons B, et al. Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology. 2015;61(4):1174–1182.
   PubMed Web of Science ®Google Scholar
• Yun H, Zhao G, Sun X, et al. Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open. 2020;10(8):1–9.
   Web of Science ®Google Scholar
• Due OT, Thakkinstian A, Thavorncharoensap M, et al. Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam. Value Heal. 2020;23(9):1180–1190.
   PubMed Web of Science ®Google Scholar
• Elsisi G, Abu Rawash A, Waked I. Economic evaluation of new HCV treatments in Egypt. Value Heal. 2017;20(9):A635.
   Web of Science ®Google Scholar
• de Lédinghen V, Lusivika-Nzinga C, Bronowicki JP, et al. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. J Viral Hepat. 2020;27(10):964–973.
   PubMed Web of Science ®Google Scholar
• Merat S, Sharifi AH, Poustchi H, et al. SD1000: high sustained viral response rate in 1361 patients with hepatitis c genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial. Clin Infect Dis. 2020;70(10):2206–2212.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Akhter TS, Khan A, et al. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020;11:1–10.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (‎including the 21st WHO model list of essential medicines and the 7th WHO model list of essential medicines for children)‎. 2019. [cited 10 June 2022]. https://apps.who.int/iris/handle/10665/330668
   Google Scholar
• Squibb BM. Important information about the discontinuation of Daklinza. 2020.
   Google Scholar
• Zoratti MJ, Siddiqua A, Morassut RE, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237.
   PubMedGoogle Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505.
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489–1496.
   PubMed Web of Science ®Google Scholar
• Fathi H, Clark A, Hill NR, et al. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. BMC Infect Dis. 2017;17(1). DOI:10.1186/s12879-017-2820-z.
   PubMedGoogle Scholar
• Pellicelli A, Messina V, Giannelli V, et al. High efficacy and safety of flat-dose ribavirin plus sofosbuvir/daclatasvir in genotype 3 cirrhotic patients. Gut Liver. 2020;14(3):357–367.
   PubMed Web of Science ®Google Scholar
• Margusino-Framiñán L, Cid-Silva P, Mena-Decea Á, et al. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice. Rev Esp Quimioter. 2019;32(2):137–144.
   PubMed Web of Science ®Google Scholar
• Teaima MH, Al-Nuseirat A, Abouhussein D, et al. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt—case study. J Pharm Policy Pract. 2021;14(1):1–11.
   PubMedGoogle Scholar
• Wei X, Zhao J, Yang L. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Glob Heal. 2020;5:1–9.
   Web of Science ®Google Scholar